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 BIOMAteRIALS
The development of a novel 
autologous blood glue aiming to 
improve osseointegration in the bone- 
implant interface
Aims
For cementless implants, stability is initially attained by an interference fit into the bone 
and osteo- integration may be encouraged by coating the implant with bioactive substances. 
Blood based autologous glue provides an easy, cost- effective way of obtaining high concen-
trations of growth factors for tissue healing and regeneration with the intention of spraying 
it onto the implant surface during surgery. The aim of this study was to incorporate nucle-
ated cells from autologous bone marrow (BM) aspirate into gels made from the patient’s 
own blood, and to investigate the effects of incorporating three different concentrations of 
platelet rich plasma (PRP) on the proliferation and viability of the cells in the gel.
Methods
The autologous blood glue (ABG) that constituted 1.25, 2.5, and 5 times concentration PRP 
were made with and without equal volumes of BM nucleated cells. Proliferation, morpholo-
gy, and viability of the cells in the glue was measured at days 7 and 14 and compared to cells 
seeded in fibrin glue.
Results
Overall, 2.5 times concentration of PRP in ABG was capable of supporting the maximum 
growth of cells isolated from the BM aspirate and maintain their characteristics. Irrespective 
of PRP concentration, cells in ABG had statistically significantly higher viability compared to 
cells in fibrin glue.
Conclusion
In vitro this novel autologous gel is more capable of supporting the growth of cells in its 
structure for up to 14 days, compared to commercially available fibrin- based sealants, and 
this difference was statistically significant.
Cite this article: Bone Joint Res 2020;9(7):402–411.
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Article focus
 The aim of this study was to incorpo-
rate the buffy layer containing nucleated 
cells including mesenchymal stem cells 
(MSCs) from autologous bone marrow 
(BM) aspirate into gels made from the 
patient’s own blood, and to investigate 
the effects of incorporating three different 
concentrations of PRP on the proliferation 
and viability of the cells in the gel.
Key messages
 This novel autologous blood glue (ABG) 
can be prepared cost- effectively and it has 
the potential to be incorporated with stem 
cells from the BM, which remain viable in it 
and retain their characteristic.
 Due to the presence of platelet rich 
plasma (PRP) in the glue, the prolifera-
tion of cells is further boosted by growth 
factors released by platelets.
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Strengths and limitations
 This novel autologous gel can be easily prepared in 
surgery and it can be sprayed onto implants, poten-
tially improving osseointegration of the implant.
 This study could benefit from investigating the poten-
tial of stem cells in the ABG to differentiate to bone.
Introduction
Each year over one million total hip arthroplasties (THAs) 
are carried out worldwide and provide patients with pain 
relief, as well as an enhanced quality of life.1,2 Despite the 
success of this surgical intervention, there is still contro-
versy over the optimal choice of implant and fixation 
methods. The lifespan of a hip implant can be described 
in two aspects, the initial stage where an implant must 
become firmly fixed and the remainder of its life cycle in 
which its stability is either preserved or lost.3 For cementless 
implants stability is initially attained by an interference fit 
into the bone and over time the surrounding bone inte-
grates with the implant surface, which may be coated with 
bioactive substance that encourages bone on- growth, 
otherwise known as osteo- integration. Depending on the 
design of the implant and on patient factors such as their 
activity level, the mean survivorship of a hip arthroplasty is 
around 90% to 95% at ten years.4
In revision cases the amount of bone stock is often 
compromised due to the loss of bone associated with 
loosening of the primary implant, adjacent osteolysis, 
and the destruction of bone caused by the removal of the 
failed primary. In these cases bone grafts may be used, 
while works have also demonstrated the utility of cells 
incorporated in gels such as fibrin glue or pre- seeded 
onto the implants to aid their retention at the bone- 
implant interface and help with bone ingrowth.5-10
Fibrin- based sealants are commonly used to reduce 
blood loss during and after surgery. These sealants are 
composed of a mixture of fibrinogen, thrombin, and 
calcium ions. Currently a commercial fibrinogen concen-
trate, Tisseel (Baxter Healthcare Corp, Deerfield, Illinois, 
USA), is used in surgery. However, the fibrinogen in Tisseel 
is isolated from pooled human plasma and although it is 
heat treated, it carries a risk of viral infection. The advan-
tages of autologous glue include an easy, cost- effective 
way of obtaining high concentrations of growth factors for 
tissue healing and regeneration by incorporating platelet 
rich plasma (PRP) that contains beneficial cytokines, such 
as platelet- derived growth factor (PDGF), transforming 
growth factor (TGF), vascular endothelial growth factor 
(VEGF), insulin- like growth factor (IGF), and epidermal 
growth factor (EGF). These proteins encourage cellular 
chemotaxis, proliferation and differentiation, removal 
of tissue debris, angiogenesis, and the laying down of 
extracellular matrix.11,12 Autologous PRP have been used 
in various orthopaedic cases, with positive outcomes.11,13 
It would be ideal to spray any form of autologous PRP gel 
onto the implant surface during surgery, and therefore it 
must be prepared relatively rapidly perioperatively and 
must gelate quickly and form a mechanical robust layer 
when sprayed onto a surface.
The aim of this study was to incorporate the buffy layer 
containing nucleated cells including mesenchymal stem 
cells (MSCs) from autologous bone marrow (BM) aspi-
rate into gels made from the patient’s own blood, and 
to investigate the effects of incorporating three different 
concentrations of PRP on the proliferation and viability of 
the cells in the gel.
Methods
Informed consent was obtained from all human volun-
teers prior to blood donation and for the BM samples. 
The study was conducted with the approval of the 
University College London Research Ethics Committee 
(07/Q0506/10). BM and blood samples were harvested 
from healthy, non- smoking patients; those with inflam-
matory, haematological, and endocrine conditions were 
excluded; all subjects were American Society of Anes-
thesiologists grade one.14 The age of patients ranged 
from 49 to 60 years old (n = 9). All blood samples 
(approximately 50 ml) were taken in citrated and plain 
blood sample tubes (BD Biosciences Vacutainer, BD, 
Oxford, UK). The blood and BM samples were collected 
from the same nine patients, all of whom were under-
going elective joint arthroplasty surgery. The glue was 
prepared under sterile conditions.
Harvesting the bone marrow aspirate from patients. BM 
aspirate was harvested from the patient's iliac crest by 
vacuum aspiration; all patients were undergoing THA for 
end- stage osteoarthritis, and consented to intraoperative 
marrow aspiration preoperatively. After aspiration the 
mono- nucleated cells were concentrated using a separa-
tion tube (ABMC harvest kit; NTL Biologica, Wantage, UK). 
One 20 ml syringe was filled with 2 ml of citrate antico-
agulant (ACD- A, Anticoagulant Citrate Dextrose Solution; 
Biomet Biologics, Warsaw, Indiana. USA) and 18 ml of BM. 
The BM was harvested using a unique jamshidi needle 
(NTL Biologica) that is perforated along its length to access 
the multiple sites within the iliac crest simultaneously. The 
BM was then spun to separate the cell- free plasma/ACD- A 
mixture from red blood cells. From a 20 ml BM aspirate that 
was spun, approximately 1.5 ml of buffy layer would be ob-
tained that would contain nucleated cells of which a small 
percentage would be MSCs. For all samples collected from 
the nine patients, all experiments were completed in tripli-
cate within each experimental condition.
Preparation of the gel. Autologous blood- derived gel 
(ABG) was prepared by spinning the blood using the 
ABMC kit (NTL Biologica). Blood was spun at 3,300 rpm 
for three minutes, to obtain the plasma which was then 
activated to obtain the thrombin component using acetic 
acid. Blood was also spun at 3,300 rpm for three minutes 
to obtain PRP and BM aspirate. PRP and BM aspirate were 
combined in equal ratios and this final mixture was then 
combined with blood serum. To form the ABG gel with 
the BM aspirate, three different concentrations of PRP 
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were investigated: 1.25 times; 2.5 times; and 5 times con-
centration. This is the concentration of the PRP after mix-
ing it with equal volumes of BM aspirate and then com-
bining it with the rest of the gel components. Mixing was 
carried out using a double- barrelled syringe that enabled 
the components to form a gel almost immediately after 
mixing. In addition, the gel thickness and the area cov-
ered by the gel could be controlled using a compressed 
air spraying system (NTL Biologica).
The same volume of BM aspirate used in the ABG gels 
was also mixed with the thrombin component, and then 
combined with aprotonin component to form fibrin glue 
(Tisseel, Baxter Healthcare Corp, Illinois USA). All ABG 
gels and fibrin glue gels were 1 ml in volume.
Rheology. Prior to assessing the utility of ABG as a coat-
ing, its viscoelastic properties were optimized by adjust-
ing the proportion of each component. Eight throm-
bin:PRP:serum ratios were investigated. The viscoelastic 
properties of each ABG produced were quantified using 
a shear rheometer (Bohlin CVO 100 Rheometer; Malvern 
Instruments, Malvern, UK). Next 40 ml of blood for ABG 
production was donated from four volunteers (n = 4) 
each. Then 1.5 ml ABG was formed on the mounting plate 
(4 mm diameter parallel plates; 0.5 mm gap). A frequen-
cy sweep was performed in dynamic mode and a fre-
quency amplitude (ω) range of 0.628 to 62.8 at 22 rad/s 
(0.001 to 10 Hz) (Bohlin CVO 100 software) (Malvern 
Instruments, Inc., Westborough, Massachusetts, USA). All 
sweeps were conducted at room temperature (approxi-
mately 23°C). The storage modulus (G’, relating to elas-
tic properties) and loss modulus (G’’, relating to viscous 
properties) of each sample was measured.
Characterization of bone marrow mesenchymal stem 
cells. The bone marrow mesenchymal stem cells (BMSCs) 
isolated with the ABMC kit were cultured in a flask and 
characterized according to the International Society for 
Stem Cell Research.15 Once colony forming units were 
established after approximately 14 days, the cells were 
passaged and characterized using flow cytometry for the 
positive CD marker expression of CD105, CD29, CD90, 
and negative CD marker expression of CD34 and CD45.16 
Briefly, 100 000 BMCs were fixed in 4% formalin for 15 
minutes at room temperature, washed with 0.5% bovine 
serum albumin (BSA), and stained with the conjugat-
ed primary antibody for one hour at room temperature 
in the dark. The cells were labelled with antimouse/rat 
CD29- fluorescein (Thermo Fisher Scientific, Walham, 
Massachusetts, USA), 17 anti- mouse/rat CD90- APC 
(Thermo Fisher Scientific), antirat CD45- APC (Thermo 
Fisher Scientific), and CD34- PE (Abcam, Cambridge, UK). 
The CD expression was compared with the isotype con-
trol. After one hour, the cells were washed with 0.5% BSA 
and analyzed on a flow cytometer (Cytoflex; Beckman 
Coulter, Brea, California, USA).
Metabolic activity/cell viability. A PrestoBlue assay (Bio- 
Rad, Kidlington, UK) was used to measure the cell prolif-
eration of the BM cells cultured within the ABG gel and 
fibrin glue at days 7 and 14. Then 10% PrestoBlue solu-
tion was added to the culture medium for 30 minutes 
and excitation at 560 nm and emission at 590 nm were 
measured using a Tecan plate reader (Infinite Pro 200 se-
ries; Tecan, Männedorf, Switzerland). The mean absorb-
ance was determined from triplicate samples. Metabolic 
activity of the cells in the ABG gel was normalized to their 
corresponding ABG gels without cells. The metabolic 
activity of the following gels was investigated: 1) 1.25× 
concentration with cells; 2) 1.25× concentration without 
cells; 3) 2.5× concentration with cells; 4) 2.5× concentra-
tion without cells; 5) 5× concentration with cells; 6) 5× 
concentration without cells; 7) fibrin glue with cells; 8) 
fibrin glue without cells.
Live/dead. To check the viability of the cells in the ABG 
gels and fibrin glue, a live/dead assay was carried out 
at days 7 and 14. The gels with and without cells were 
washed with PBS and incubated in Calcein AM (Thermo 
Fisher Scientific, UK) and Ethidium Homodimer (Thermo 
Fisher Scientific, UK) for 30 minutes at 37°C, 5% Co2, in 
the dark. After incubation, the gels were washed with PBS 
and viewed under a fluorescent microscope (Apotome.2; 
Carl Zeiss Microscopy, Jena, Germany).
Phalloidin stain for actin filaments and the cell cy-
toskeleton. The ABG gels were fixed in 10% buffered 
Formaldehyde for 30 minutes, washed with PBS, and 
then incubated with Phalloidin and Hoescht mixture for 
30 minutes at room temperature. The stain was then 
washed off with PBS thrice to remove any excess stain, 
and the gels were viewed under a fluorescent microscope 
(Apotome.2).
Histology. Histology was performed as per our previous 
studies.17 Briefly, the ABG and fibrin glue gels were fixed 
in 10% buffered Formaldehyde, dehydrated in a series of 
increasing alcohol concentrations, treated with chloro-
form for two days to de- fat the tissue, and then embed-
ded in wax. Sections measuring 5 µm thick were made 
using a microtome at the centre of each gel (Thermo 
Fisher Scientific). Samples were de- waxed twice in xy-
lene, placed in two changes of 100% alcohol, and then 
hydrated in serial dilutions of alcohol. After hydration, 
samples were stained in haematoxylin, a nuclear stain, for 
five to ten minutes. The excess stain was washed off by 
immersing the slides in water for five minutes. Samples 
were then differentiated in 0.5% hydrochloric acid (HCL; 
made up in 70% alcohol) and washed using water. After 
removing the acid- alcohol, samples were counterstained 
in 1% eosin for three to four minutes, washed in water, 
and dehydrated by serial dilutions of alcohol. Finally, 
samples were cleaned by xylene and mounted under 
coverslips using Pertex Mounting Medium (CellPath, 
Newtown, UK). Samples were observed under a light 
microscope (KS-300 Zeiss; Carl Zeiss Microscopy) at 10× 
magnification. The area containing stem cells in the gel 
was calculated by counting the number of quadrants 
with spindle shaped cells and dividing this by the total 
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Fig. 1
Rheological analysis of platelet rich plasma (PRP) gels. The graphs show the elastic (blue) and viscous (green) modulus of the different types of gels (Gel A – 
H) at different thrombin and platelet concentrations. A higher elastic modulus compared to the viscous modulus without any crossover demonstrates effective 
cross- linking of the gels. Error bars represent standard error (SE) ± 1 (n = 4).
number of quadrants covering the whole gel area. This 
value was then expressed as a percentage
the retention of stem cell characteristics of cells embedded 
in the gel. BM aspirate was incorporated in the gels and 
although it was established that the cells obtained from 
this aspirate expressed stem cell characteristics, it was im-
portant for us to determine whether these characteristics 
were maintained after 14 days in a gel. As such, after 14 
days the gels were fixed, prepared for wax histology (as 
described above), and stained for CD90 and CD29 using 
immunofluorescence.
Statistical analysis. Normality was determined using 
the Kolmogorov- Smirnov and Shapiro- Wilk tests and 
where the data was normal, comparison was made using 
independent- samples t- test. Where the data was non- 
parametric comparison was made using Mann- Whitney 
U test with a Bonferroni correction. All data was analyz-
ed using SPSS version 24 (IBM, Armonk, New York, USA) 
with p < 0.05 considered to be significant.
Results
Rheology. To select the optimized gel formulation, it was 
important for the gel to have the following mechanical 
properties as measured rheologically: 1) the elastic and 
viscous modulus should not cross over as this demon-
strates episodes of viscosity and elasticity, indicating a 
lack of network structure typical of an unlinked polymer; 
and 2) values of elastic modulus (G’) should remain high-
er than viscous modulus (G’’), indicating predominant-
ly elastic properties and the presence of a 3D network 
structure.
In accordance with these properties, gel B had the 
highest values of G’ and G’’ over the higher frequency 
range (5 to 50 rad/s), with the two different types of 
moduli not crossing over. Therefore, gel B possesses the 
highest cohesiveness and network concentration at 23°C 
(Figure 1).
Cell viability. Phalloidin and live/dead staining of the 
cells up to 14 days showed that the gels supported the 
proliferation and growth of cells. At 14 days, it was evi-
dent that cells of two different morphologies were pres-
ent; a rounder type and an elongated type. BM stem 
cells grown from the BM aspirate on tissue culture sur-
faces were characterized using CD marker expression at 
passage 2 (Figures 2 and 3). Over 70% of these cells ex-
pressed CD29, CD90, and CD105. Additionally, less than 
5% of the cell population from this BM aspirate expressed 
CD34 and CD45 (Figure 4).
effect of PRP concentration on cell viability. It was ob-
served that the concentration of platelets in the gel had 
an effect on the viability of MSCs embedded in the gels. 
A 2.5 times concentration of PRP produced optimum 
conditions for cell proliferation. Interestingly, 5 times 
concentration of PRP was observed to reduce the growth 
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Fig. 2
Proliferation and Live/Dead stain of bone marrow mesenchymal stem cells (BMSCs) at days 7 and day 14 for different concentration of platelet rich plasma 
(PRP) in gels; 1.25, 2.5, and 5 times concentration of PRP. These photos are taken of gels made from one patient at 2.5× magnification. The 5 times 
concentration of PRP in the autologous gel was observed to reduce the proliferation of BMSCs, although quantification using PrestoBlue (metabolic activity) 
showed that this was not significantly different to the other concentrations of gels (n = 8). However, there was a significant difference for the mean metabolic 
activity between fibrin glue and all concentrations of gels at days 7 and day 14. Magnification ×10.
of the cells in the gel at both days 7 and 14. The 5 times 
concentration gels were also observed to reabsorb fast-
er than the 2.5 times and 1.25 times concentration gels. 
Although the differences were not statistically significant, 
MSCs cultured in the 2.5 times PRP concentration main-
tained the highest proliferation at day 7 (mean 11,731 
nm (SD 4,416)) and at day 14 as well (mean 11,393 nm 
(SD 6,001)) (Figure 2). High variability in the proliferation 
data was observed because of variability in PRP between 
patients.
Retention of stem cell characteristics. Immunofluorescence 
staining showed that after 14 days in the gel, the human 
BMSCs retained their stem cell characteristics as they con-
tinued to strongly express CD29 and CD90 (Figure 5). The 
spindle- like shape of the cells was clearly visible. This ex-
pression of CD29 and CD90 was not visible in gels without 
cells. This shows that the components of the gel and PRP 
did not influence the characteristics of the MSCs and their 
CD marker expression, and the nucleated cells which were 
embedded in the gel were able to proliferate into stem cells.
Histological analysis. Histologically at day 7, the percent-
age area occupied by the cells was statistically significant-
ly higher in the gels with PRP groups compared to gels 
with no buffy layer cells and cells + fibrin glue. This was 
also evident at day 14, showing that the ABG gel support-
ed cell growth and allowed the cells to proliferate. Even 
though the 2.5 times concentration gel had the highest 
cell number, there was no significant difference between 
the gels of different PRP concentrations and this could be 
due to large variability between patients. Between days 7 
and 14, a significant difference in cell area was only ob-
served in 1.25 times concentration gels (Figure 6).
Discussion
This study investigated the behaviour of human MSCs 
in an autologous gel made from venous blood. The cells 
isolated by the ABMC kit were identified to be MSCs by 
flow cytometry and were observed to be viable in the 
gel up to 14 days, until the gel was reabsorbed. Using 
Calcein AM and Ethidium Homodimer, as well as Pres-
toBlue measurements, the cells were also observed to 
be viable in the gel up to 14 days. Histology and actin 
staining demonstrated that two different types of cells 
were present in the gel; cells with a round morphology, 
most likely to be nucleated blood cells, and spindle- 
shaped fibroblastic like cells most likely to be MSCs. At 
the later timepoints cells with a fibroblastic morphology 
predominated, indicating that the gel enhanced the 
proliferation of these cells disproportionately compared 
with the nucleated blood cells. BMSCs are an important 
component of the gel because they have the potential 
to differentiate to bone, helping with the integration of 
the implant to the bone surface.15 Indeed it has been 
shown that bone contact and ingrowth of hydroxyapatite 
coated implants was statistically significant, improved 
by spraying autologous MSCs suspended in fibrin glue 
in ovine models.9 The difference between this and our 
current study is that we are using minimally manipulated 
cells in an autologous glue derived from the patient’s 
own blood.
Although the use of ABG in orthopaedic treatments 
needs to be established, the demand for autologous 
fibrin glue has increased compared to commercially avail-
able products. Its application varies from use in wound 
covering to maxillofacial surgery and all these various 
gels/glues have different compositions of blood, with PRP 
forming the main component.18–22 PRP contains growth 
factors that can encourage the growth of cells. From this 
study, 5 times concentration was seen to reduce MSC 
proliferation at day 7 and day 14. In addition, 2.5 times 
concentration of PRP supported the growth of MSCs in 
the gel, and cell proliferation was higher at this concen-
tration than at 1.25 times or without any PRP. Although 
PRP contains growth factors such as transforming growth 
factor beta (TGF-β), VEGF, and IGF-1, which enhances 
cell proliferation, it also contains thrombospondin-1 
VOL. 9, NO. 7, JULY 2020
THE DEVELOPMENT OF A NOVEL AUTOLOGOUS BLOOD GLUE AIMING TO IMPROVE OSSEO- INTEGRATION IN THE BONE- IMPLANT INTERFACE 407
Fig. 3
Phalloidin (magnification ×20), live/dead (magnification ×10), and Haemotoxylin and Eosin staining (magnification ×10) of the cells in the 2.5 times 
concentration autologous blood gel after 14 days. Images A, C, and E are gels without bone marrow (BM) stem cells and Images B, D, and F are gels with 
BM stem cells cultured in them. The cells were stained with Phalloidin (A and B), Live/Dead stain (C and D), and Haemotoxylin and Eosin stain (E and F). 
Haemotoxylin and Eosin staining Fibrin glue without cells (G), and with cells (H), with cells circled.
(TSP-1), and high concentrations of this protein inhibit 
proliferation, cell adhesion, and angiogenesis.23 This 
could explain why stem cell growth was reduced at 5 
times PRP concentrations. Although we did not find any 
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Fig. 4
Flow cytometry results of cells obtained from the bone marrow aspirate isolated from the buffy layer. The cells had positive stem cell markers for CD29, CD90, 
Stro1, CD105, and negative expression of CD34 and CD45. The red histograms are isotype controls and green histograms show the expression of the CD 
markers (n = 9). The stains used were Phycoerythrin (PE), Allophycocyanin (APC), and Fluorescein isothiocyanate (FITC).
significant differences in cell numbers and metabolic 
activity between different PRP concentrations, it has been 
reported that high concentrations of PRP have an inhib-
itory effect on bone formation in rabbits.24 The highest 
concentration of PRP did exhibit the lowest cell metabolic 
activity but results were insignificant, which could be due 
to variability in platelets between different patients. Yet 
PrestoBlue assays may not truly represent changes in cell 
number, as changes in reaction product may be a result of 
increased metabolic activity or increased cell number. As 
such, effects relating to cell number may require further 
investigation by normalizing the PrestoBlue results using 
DNA assays.
The results from this study are similar to a study by 
Jalowiec et al.25 They observed that PRP gels, formed 
using PRP and the thrombin component from Tisseel 
Baxter, formed an effective carrier for BMSCs in terms of 
cell viability and proliferation.25 This is similar to our work, 
where we have shown that an autologous fibrin- base 
scaffold/gel is much better at supporting the proliferation 
and viability of chondrocytes and BMSCs compared to 
the commercial Fibrin glue (Tisseel, Baxter. UK).26
Cravens et al27 have shown that commercial fibrin 
glues have a higher compressive strength than autolo-
gous gels. Although this is an important property, the 
commercial glue lacks the growth factors provided by 
PRP and we have shown that the proliferation of cells 
within the autologous gel increased, and this was statis-
tically significant compared with the fibrin glue. It is also 
important for such a glue that carries cells to initially act 
as an effective scaffold to support cell proliferation and 
differentiation, and also biodegrade within a certain time 
frame to enable neovascularization. Additionally, it has 
been reported that Aprotinin, which is added to commer-
cial fibrin glues to provide delayed fibrinolysis of the 
clot, demonstrates a slower regeneration of granulation 
tissue, thus aprotinin may not be beneficial where the 
glue is being used as a carrier for cells and tissue regen-
eration that replaces the glue is required.28 One of the 
limitations of this study is that we did not establish the 
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Fig. 5
Immunofluorescence staining of mesenchymal stem cells (MSCs) in the gel after 14 days in 2.5 times concentration gels. The gels containing bone marrow 
MSCs were stained for CD29- APC (A) and CD90- APC (C). Gels without any cells were also stained for CD29 (B) and CD90 (D). All gels were counter- stained 
with DAPI and viewed at a magnification of ×5. A control gel containing MSCs was stained with DAPI only to establish any background staining. Spindle- 
shaped cells visible in the gel had stained positive for CD29 and CD90.
Fig. 6
Percentage cell area for the different platelet rich plasma (PRP) concentration gels and fibrin glue, with and without cells at day 7 (A) and day 14 (B). When 
implemented with bone marrow aspirate, the ABG had a statistically significantly higher cell area compared to fibrin glue after days 7 and 14. *p < 0.05.
resorption rates of the different concentrations of the gels 
and whether this is cell mediated or not. Further studies 
may be needed to answer this important question of this 
autologous gel’s biodegradability and its ability to act as 
an effective scaffold for cells.
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The reasoning behind encapsulating MSCs into gels 
was to investigate whether this ABG could be used as a 
scaffold and delivery system of cells as well as growth 
factors. This is important because clinically, where 
patients suffer from impaired wound healing and tissue 
loss, the ABG could provide stem cells that have the 
potential to differentiate to the surrounding tissue, and 
this would be further boosted with growth factors from 
the PRP in the glue. We also showed that the stem cells 
embedded in the gel retained their stem cell characteris-
tics. In vivo, autologous fibrin glue generated from the 
plasma of rabbit blood has been used in healing osteo-
chondral fractures of the distal femur of rabbits, and they 
found improved cellularity in the glue group compared 
to the control group. In this study cells were not incor-
porated into the glue before it was implanted, and 
possibly the positive results seen could have been further 
enhanced if stem cells had been included.29
Our study demonstrates that a 2.5 times concentra-
tion of PRP in ABG is capable of supporting the growth 
of cells isolated from the BM aspirate. In vitro this autol-
ogous gel is capable of supporting cells in its structure 
for up to 14 days, and the cells remain viable during this 
period of time. Further avenues for exploration include 
the utility of the gel- cell as a suspension that can be 
applied to implants. If the cell viability is maintained in 
the spray form as it is in gel, then there may be profound 
implications for spraying a PRP- stem cell suspension on 
implants to improve osseointegration.30
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